Format

Send to

Choose Destination
Infection. 2018 Apr;46(2):147-163. doi: 10.1007/s15010-017-1093-1. Epub 2017 Nov 2.

Current and future challenges in HCV: insights from an Italian experts panel.

Author information

1
Infectious Diseases, Polyclinic of Rome Tor Vergata, Rome, Italy.
2
Infectious Diseases Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
3
Humanitas University and Humanitas Research Hospital, Rozzano, Milan, Italy.
4
Humanitas Clinical and Research Center, Humanitas Research Hospital, Rozzano, Milan, Italy.
5
Department of Experimental and Clinical Medicine, Interdepartmental Centre MASVE, University of Florence, Florence, Italy.
6
Sezione di Gastroenterologia e Epatologia, DiBiMIS, University of Palermo, Palermo, Italy.
7
Unit of Infectious Diseases, Department of Medical Sciences, Amedeo di Savoia Hospital, University of Turin, Turin, Italy.
8
Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
9
Infectious and Tropical Diseases Unit, Umberto I Hospital-"Sapienza" University, Rome, Italy.
10
Department of Internal Medicine, Gastroenterology Unit, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.
11
Gastroenterology and Liver Unit, DiBiMIS, University of Palermo, Palermo, Italy. antonio.craxi@unipa.it.

Abstract

BACKGROUND:

The recent availability of direct acting antiviral drugs (DAAs) has drastically changed hepatitis C virus (HCV) treatment scenarios, due to the exceedingly high rates of sustained virological response (SVR) and excellent tolerability allowing for treatment at all disease stages.

METHODS:

A panel of Italian experts was convened twice, in November 2016 and January 2017, to provide further support on some open issues and provide guidance for personalized HCV care, also in light of forthcoming regimens.

RESULTS AND CONCLUSIONS:

Treatment recommendations issued by international and national liver societies to guide clinicians in the management of HCV infection are constantly updated due to accumulating new data. Such recommendations may not be applicable to all healthcare settings for a variety of reasons. Moreover, some gaps still remain and the spectrum of patients to be treated is also evolving.

KEYWORDS:

Comorbidities; DAAs; HCV; Treatment

PMID:
29098647
DOI:
10.1007/s15010-017-1093-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center